Mayne says it’s not on hook for break fee over failed Cosette merger
Mayne Pharma says it, and not US drug maker Cosette, has terminated their $672 million merger agreement and that it is therefore not on the hook for a break fee.
Mayne Pharma says it, and not US drug maker Cosette, has terminated their $672 million merger agreement and that it is therefore not on the hook for a break fee.
For information on rights and reprints, contact subscriptions@lawyerly.com.au